symptoms of chronic nasal or pulmonary infection, it continues with evidence of widespread inflammation [1] . Later clinical and histopathological studies have confirmed that WG follows a two-phase course [5] . In most patients the upper and/or lower respiratory tract is primarily affected (initial phase). In a number of these cases non-specific chronic inflammation of the sinuses or ears may be present for months to years before the diagnosis of WG is made. So the disease gradually evolves into a locoregionally restricted disease with more specific signs such as nasal crusting with epistaxis, antral pain, oral ulceration, or subglottis stenosis. Biopsy [6] may show granulomatous inflammation, necrosis (microabcesses; collagen necrosis) and vasculitis (mostly: < 50% in nasal specimens) but there are no clinical signs of generalized vasculitis. This restricted form can then turn into the classic generalized vasculitic disease (generalized phase) ultimately leading to a life-threatening course dominated by necrotizing glomerulonephritis, pulmonary capillaritis etc. The knowledge that WG follows a two-phase course, together with the increasing identification of cases during the initial phase due to the diagnostic use of antineutrophil cytoplasmic autoantibodies (ANCA), provide a rationale for a stage adapted treatment ofWG.
Alternative treatment modalities

Trimethoprim-sulphamethoxazole (Bactrim, (T/S)
While T/S may have the capacity to induce remission in the initial phase of WG [7] , the question of whether it may actually prolong the initial phase is currently being investigated in double-blind controlled studies. Recent experience does not indicate that T/S can prevent relapse of generalized WG in remission and thus it does not appear suited for treatment of renal WG [8] .
Pulse CP Inconsistent results were obtained in 12 patients with generalized WG treated with pulse CP [9] , Similarly W. L. Gross and N. Rasmussen the NIH [10] reported only temporary benefit in 13 of a high cANCA titre [13] . In conclusion, in life-14 patients treated with the same pulse CP regimen; threatening situations and/or in cases of severe (multilack of response and failure to sustain improvement organ involvement) generalized WG the standard or to tolerate continued treatment was noted in 79% protocol appears to be superior to pulse CP plus GC. of patients. In contrast, two nephrological groups [11, 12] reported the outcome after pulse CP therapy Mpthntrexatp to be comparable with that of the standard protocol. memoirexaie These differences may be ascribed to the fact that all Hoffman et al. recently used low-dose (20-the nephrological patients had renal involvement, 30 mg/weekly) MTX plus GC in 29 WG patients whereas only 50% of the NIH patients and only 32% without 'immediately life-threatening disease', of the patients in LUbeck/Bad Bramstedt showed signs although 12 patients (41%) did have active glomeruloof renal disease when starting treatment. In addition nephritis [14] . This produced a marked improvement the group studied in Chapel-Hill [12] was heterogen-in 76% and remission in 69% of the patients! However, eous: only 19 of 37 WG patients had cANCA and a three of 29 (10%) suffered from Pneumocystis carinii majority of the other patients had pANCA, suggesting pneumonia during the first month of treatment (includthat cases of microscopic polyangiitis were included, ing prednisone 60 mg per day). Therefore, in order to find clinical and/or immunological markers affecting the response to pulse c .
• A (C A) CP, we studied its efficacy in 43 cANCA-positive and * P ' ) biopsy-proven WG patients (Table 1) . Fifty-eight per-Until now CsA has been used only as a back-up cent of the patients did not respond to pulse CP treatment in WG. In four patients with poor response treatment! Collectively, a poor response was seen in to (oral) CP or with intolerable side-effects, CsA was patients with generalized disease involving more than able to control disease activity at dosages between 5 four organ systems (mainly the heart, nervous system, and 10 (!) mg/kg per day [15] . Recently, Allen et al.
eyes, skin) with constitutional symptoms and with [16] presented data on patients with active WG under- Wegener's granulomatosis going combined CsA and low-dose GC therapy. CsA was effective at initial doses of up to 5 mg/kg/day, but mild flare-ups occurred when this was lowered to 2 mg/kg/day. Schmitt et al. [17] reported on 20 patients who received renal transplants between 1982 and 1993. Treatment before transplant consisted of oral CP and GC in 18 patients, and of pulse CP and GC or azathioprine plus GC in one patient each. At the time of transplant, six patients showed symptoms of active disease. Nevertheless, 18 patients are still alive with functioning grafts (mean creatinine: 1.7 mg/%) and 16 are in complete remission. These data demonstrate that the rate of survival and graft function in patients with WG is comparable to that of other transplant recipients, so patients with still active WG need not be excluded from transplantation. Frequencies of relapse after transplant are given in Figure 1 . One patient (on CsA + GC) died 46 months after transplant during a severe relapse involving the lungs and the gut, but not the kidneys; all other patients suffering less severe relapses were treated successfully by adding CP or increasing the dosage of GC or azathioprine. These data indicate that immunosuppressive therapy after transplantation must not necessarily include CP and that CsA is effective under such circumstances.
High-dose intravenous administered invnunoglobulin (1VIG)
The ability of FVTG to diminish vasculitic features was described recently [18, 19] . IVIG was given to 26 patients (WG, 14; microscopic polyangiitis, 11; rheumatoid vasculitis, 1), mostly refractory to or intolerant of GC and cytotoxic drugs, in whom it was necessary to escalate therapy. They received Sandoglobulin 2 g/kg over 5 days. All appeared to improve after FVIG, with 13 of 26 achieving full remission. The benefit was sustained in 18 of 26 at 12 months. Allowing for changes in other medications, 19 of 26 were in full remission after 1 year, six in partial remission while one had died of septic complications. In another study FVTG was given to eight patients with WG and one with systemic pANCA-associated vasculitis, none of whom had reached complete remission under standard therapy [20] . The response was measured by blind interdisciplinary clinical assessment (ENT, etc.), MRI of the head, and immunodiagnostic analyses. All nine patients were treated with Venimmune (0.4 g/kg/day for 5 days). Sixty percent of the patients responded to therapy by showing improvement of single disease manifestations but complete remission was not experienced in any of the patients. FVTG may thus play a role as an adjuvant to conventional therapy in patients with progressive disease.
Monoclonal-antibody therapy
This was introduced for treatment of vasculitis in 1990 [21] ; a case of severe vasculitis treated several times with an anti-CDw52 antibody (Campath 1H) responded with significant but only transient improvement. Remission lasting for more than 2 years, however, was achieved by following anti-CDw52 with injection of an anti-CD4 antibody. The same group now reports on four patients with primary and secondary vasculitides (microscopic polyangiitis, Sjogren's syndrome, Behcet's disease) who were unresponsive to immunosuppressive drugs but who received 'substantial and sustained benefit' from Campath 1H and hIgGlCD4 [22] . Similar results have been obtained in a few patients with systemic WG (C. M. Lockwood, personal communication). Two other groups have reported on the successful treatment of two severe and untractable cases of relapsing polychondritis with vasculitis using a mouse and chimeric anti-CD4 monoclonal antibody [23, 24] .
Conclusion
Experience in the treatment of WG has largely come from treatment of patients in the generalized phase, which is frequently associated with renal involvement. In an attempt to reduce the toxicity of treatment, several of the less toxic treatment modalities described above may be applied not only in the generalized phase-before renal involvement complicates the course of the disease-but also in the initial phase in order to obtain lasting remissions or at least to postpone the necessity for standard therapy. Further investigations are obviously needed, one initiative being the formation of the 'European Community co-ordination of therapeutic trials in systemic vasculitis (ECSYSVASTRIAL)'.
